Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA; email:
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:201-222. doi: 10.1146/annurev-genom-083117-021329. Epub 2018 Apr 25.
In many respects, genetic studies in cystic fibrosis (CF) serve as a paradigm for a human Mendelian genetic success story. From recognition of the condition as a heritable pathological entity to implementation of personalized treatments based on genetic findings, this multistep pathway of progress has focused on the genetic underpinnings of CF clinical disease. Along this path was the recognition that not all CFTR gene mutations produce the same disease and the recognition of the complex, multifactorial nature of CF genotype-phenotype relationships. The non- CFTR genetic components (gene modifiers) that contribute to variation in phenotype are the focus of this review. A multifaceted approach involving candidate gene studies, genome-wide association studies, and gene expression studies has revealed significant gene modifiers for multiple CF phenotypes. The bold challenges for the future are to integrate the findings into our understanding of CF pathogenesis and to use the knowledge to develop novel therapies.
在许多方面,囊性纤维化 (CF) 的遗传研究为人类孟德尔遗传成功故事树立了典范。从将该病症识别为可遗传的病理实体,到根据遗传发现实施个性化治疗,这一多步骤的进展途径侧重于 CF 临床疾病的遗传基础。在此过程中,人们认识到并非所有 CFTR 基因突变都会产生相同的疾病,并且认识到 CF 基因型-表型关系的复杂性和多因素性质。本文重点介绍了导致表型变异的非 CFTR 遗传成分(基因修饰因子)。候选基因研究、全基因组关联研究和基因表达研究等多方面的方法揭示了多个 CF 表型的重要基因修饰因子。未来的艰巨挑战是将这些发现整合到我们对 CF 发病机制的理解中,并利用这些知识开发新的治疗方法。